Bristol-myers Squibb Compnay

Merck Sharp + Dohme Corp.

Five Prime Therapeutics, Inc.

Xiao Min Schebye

Mark J Selby

Alan J Korman

Guodong Chen

Michelle Minhua Han

Ekaterina G Deyanova

Christine Bee

Richard Y Huang

Hong-An Truong

Paul O Sheppard

Brigitte Devaux

Huiming Li

Daniel F Ardourel

Andy X Deng

Anan Chuntharapai

Michelle Renee Kuhne

Leonard G Presta

Grigori Ermakov

Douglas J Hodges

Nils Lonberg

Linda Liang

Andrew Rankin

Xiaodi Deng

Joseph Toth

Diana Yuhui Chen

Richard Yu-Cheng Huang

Hong-An Troung

Michelle Kuhne

Grigori P Ermakov

Grigory P Ermakov

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies binding to ILT4

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.

Anti-GITR antibodies

Growing community of inventors

San Carlos, CA, United States of America

Xiao Min Schebye